{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:02:20Z","timestamp":1792677740527,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nrcardio.2013.70","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T10:33:18Z","timestamp":1368527598000},"page":"387-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":296,"title":["Therapeutic angiogenesis for critical limb ischaemia"],"prefix":"10.1038","volume":"10","author":[{"given":"Brian H.","family":"Annex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"BFnrcardio201370_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archinte.163.8.884","volume":"163","author":"JJ Belch","year":"2003","unstructured":"Belch, J. J.  et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch. Intern. Med. 163, 884\u2013892 (2003).","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. S","key":"BFnrcardio201370_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren, L.  et al. Inter-society consensus for the management of peripheral arterial disease (TASCII). J. Vasc. Surg. 45 (Suppl. S), S5\u2013S67 (2007).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger, V. L.  et al. Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association. Circulation 123, e18\u2013e209 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570\u20132581 (2002).","journal-title":"JAMA"},{"key":"BFnrcardio201370_CR5","first-page":"142","volume":"12","author":"J Dormandy","year":"1999","unstructured":"Dormandy, J., Heeck, L. & Vig, S. The fate of patients with critical leg ischemia. Semin. Vasc. Surg. 12, 142\u2013147 (1999).","journal-title":"Semin. Vasc. Surg."},{"key":"BFnrcardio201370_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.295.5.547","volume":"295","author":"GJ Hankey","year":"2006","unstructured":"Hankey, G. J., Norman, P. E. & Eikelboom, J. W. Medical treatment of peripheral arterial disease. JAMA 295, 547\u2013553 (2006).","journal-title":"JAMA"},{"key":"BFnrcardio201370_CR7","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/01.CIR.91.5.1472","volume":"91","author":"WR Hiatt","year":"1995","unstructured":"Hiatt, W. R., Hoag, S. & Hamman, R. F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 91, 1472\u20131479 (1995).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR8","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","volume":"344","author":"WR Hiatt","year":"2001","unstructured":"Hiatt, W. R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344, 1608\u20131621 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201370_CR9","first-page":"499","volume":"21","author":"R Fontaine","year":"1954","unstructured":"Fontaine, R., Kim, M. & Kieny, R. Surgical treatment of peripheral circulation disorders [German]. Helv. Chir. Acta 21, 499\u2013533 (1954).","journal-title":"Helv. Chir. Acta"},{"key":"BFnrcardio201370_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0741-5214(00)81002-2","volume":"31","author":"JA Dormandy","year":"2000","unstructured":"Dormandy, J. A. & Rutherford, R. B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J. Vasc. Surg. 31, S1\u2013S296 (2000).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jvs.2005.11.041","volume":"43","author":"EP Brass","year":"2006","unstructured":"Brass, E. P.  et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J. Vasc. Surg. 43, 752\u2013759 (2006).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0140-6736(01)06351-6","volume":"358","author":"K Ouriel","year":"2001","unstructured":"Ouriel, K. Peripheral arterial disease. Lancet 358, 1257\u20131264 (2001).","journal-title":"Lancet"},{"key":"BFnrcardio201370_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jvs.2007.07.049","volume":"46","author":"SA Berceli","year":"2007","unstructured":"Berceli, S. A.  et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J. Vasc. Surg. 46, 1173\u20131179 (2007).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27\u201331 (1995).","journal-title":"Nat. Med."},{"key":"BFnrcardio201370_CR15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1161\/01.CIR.0000159345.00591.8F","volume":"111","author":"M Simons","year":"2005","unstructured":"Simons, M. Angiogenesis: where do we stand now? Circulation 111, 1556\u20131566 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR16","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1161\/01.CIR.0000128595.79378.FA","volume":"109","author":"DW Losordo","year":"2004","unstructured":"Losordo, D. W. & Dimmler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 109, 2487\u20132491 (2004).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1126\/science.275.5302.964","volume":"275","author":"T Asahara","year":"1997","unstructured":"Asahara, T.  et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964\u2013967 (1997).","journal-title":"Science"},{"key":"BFnrcardio201370_CR18","first-page":"H1255","volume":"273","author":"WD Ito","year":"1997","unstructured":"Ito, W. D.  et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am. J. Physiol. 273, H1255\u2013H1265 (1997).","journal-title":"Am. J. Physiol."},{"key":"BFnrcardio201370_CR19","first-page":"81","volume":"111","author":"JL Robbins","year":"2011","unstructured":"Robbins, J. L.  et al. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J. Appl. Phys. 111, 81\u201386 (2011).","journal-title":"J. Appl. Phys."},{"key":"BFnrcardio201370_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jvs.2005.01.037","volume":"41","author":"CD Askew","year":"2005","unstructured":"Askew, C. D.  et al. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J. Vasc. Surg. 41, 802\u2013807 (2005).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1358863X07084858","volume":"12","author":"RG Mitchell","year":"2007","unstructured":"Mitchell, R. G.  et al. Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc. Med. 12, 285\u2013290 (2007).","journal-title":"Vasc. Med."},{"key":"BFnrcardio201370_CR22","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1161\/ATVBAHA.111.230441","volume":"31","author":"BD Duscha","year":"2011","unstructured":"Duscha, B. D.  et al. Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler. Thromb. Vasc. Biol. 31, 2742\u20132748 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio201370_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1358836X0100600103","volume":"6","author":"AW Gardner","year":"2001","unstructured":"Gardner, A. W. & Killewich, L. A. Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. Vasc. Med. 6, 9\u201314 (2001).","journal-title":"Vasc. Med."},{"key":"BFnrcardio201370_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0008-6363(99)00191-1","volume":"43","author":"W Schaper","year":"1999","unstructured":"Schaper, W. & Buschmann, I. Arteriogenesis, the good and bad of it. Cardiovasc. Res. 43, 835\u2013837 (1999).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201370_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1152\/physiolgenomics.00047.2007","volume":"30","author":"D Chalothorn","year":"2007","unstructured":"Chalothorn, D.  et al. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol. Genomics 30, 179\u2013191 (2007).","journal-title":"Physiol. Genomics"},{"key":"BFnrcardio201370_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yjmcc.2003.10.002","volume":"36","author":"ED de Muinck","year":"2004","unstructured":"de Muinck, E. D. & Simons, M. Re-evaluating therapeutic neovascularization. J. Mol. Cell. Cardiol. 36, 25\u201332 (2004).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrcardio201370_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/01.RES.0000124603.46777.EB","volume":"94","author":"M Heil","year":"2004","unstructured":"Heil, M., Ziegelhoeffer, T., Mees, B. & Schaper, W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ. Res. 94, 573\u2013574 (2004).","journal-title":"Circ. Res."},{"key":"BFnrcardio201370_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0008-6363(03)00258-X","volume":"58","author":"A Luttun","year":"2003","unstructured":"Luttun, A. & Carmeliet, P. De novo vasculogenesis in the heart. Cardiovasc. Res. 58, 378\u2013389 (2003).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201370_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/wsbm.92","volume":"2","author":"F Mac Gabhann","year":"2010","unstructured":"Mac Gabhann, F., Qutub, A. A., Annex, B. H. & Popel, A. S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 694\u2013707 (2010).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"BFnrcardio201370_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","volume":"29","author":"N Ferrara","year":"2009","unstructured":"Ferrara, N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789\u2013791 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio201370_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1752-0509-5-59","volume":"5","author":"P Vempati","year":"2011","unstructured":"Vempati, P. Mac Gabhann, F. & Popel, A. S. Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst. Biol. 5, 59 (2011).","journal-title":"BMC Syst. Biol."},{"key":"BFnrcardio201370_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1109\/MEMB.2009.931791","volume":"28","author":"AA Qutub","year":"2009","unstructured":"Qutub, A. A., Mac Gabhann, F., Karagiannis, E. D., Vempati, P. & Popel, A. S. Multiscale models of angiogenesis. IEEE Eng. Med. Biol. Mag. 28, 14\u201331 (2009).","journal-title":"IEEE Eng. Med. Biol. Mag."},{"key":"BFnrcardio201370_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1752-0509-2-77","volume":"2","author":"MO Stefanini","year":"2008","unstructured":"Stefanini, M. O., Wu, F. T., Mac Gabhann, F. & Popel, A. S. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst. Biol. 2, 77 (2008).","journal-title":"BMC Syst. Biol."},{"key":"BFnrcardio201370_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1152\/physiolgenomics.00031.2009","volume":"38","author":"FT Wu","year":"2009","unstructured":"Wu, F. T.  et al. Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: Effects of transendothelial and lymphatic macromolecular transport. Physiol. Genomics 38, 29\u201341 (2009).","journal-title":"Physiol. Genomics"},{"key":"BFnrcardio201370_CR35","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/CIRCRESAHA.107.160630","volume":"101","author":"S Hazarika","year":"2007","unstructured":"Hazarika, S.  et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ. Res. 101, 948\u2013956 (2007).","journal-title":"Circ. Res."},{"key":"BFnrcardio201370_CR36","doi-asserted-by":"publisher","first-page":"H153","DOI":"10.1152\/ajpheart.00254.2003","volume":"286","author":"F Mac Gabhann","year":"2004","unstructured":"Mac Gabhann, F. & Popel, A. S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286, H153\u2013H164 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio201370_CR37","first-page":"570","volume":"12","author":"F Mac Gabhann","year":"2010","unstructured":"Mac Gabhann, F., Annex, B. H. & Popel, A. S. Gene therapy from the perspective of systems biology. Curr. Opin. Mol. Ther. 12, 570\u2013577 (2010).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"BFnrcardio201370_CR38","doi-asserted-by":"publisher","first-page":"H2174","DOI":"10.1152\/ajpheart.00365.2009","volume":"298","author":"FT Wu","year":"2010","unstructured":"Wu, F. T.  et al. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am. J. Physiol. Heart Circ. Physiol. 298, H2174\u2013H2191 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio201370_CR39","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201370_CR40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger, D. R.  et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983\u2013985 (1983).","journal-title":"Science"},{"key":"BFnrcardio201370_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"S Rajagopalan","year":"2003","unstructured":"Rajagopalan, S.  et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933\u20131938 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.1312256","volume":"255","author":"C de Vries","year":"1992","unstructured":"de Vries, C.  et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989\u2013991 (1992).","journal-title":"Science"},{"key":"BFnrcardio201370_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0140-6736(96)03361-2","volume":"348","author":"JM Isner","year":"1996","unstructured":"Isner, J. M.  et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370\u2013374 (1996).","journal-title":"Lancet"},{"key":"BFnrcardio201370_CR44","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(02)08937-7","volume":"359","author":"RJ Lederman","year":"2002","unstructured":"Lederman, R. J.  et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359, 2053\u20132058 (2002).","journal-title":"Lancet"},{"key":"BFnrcardio201370_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/hc0802.104407","volume":"105","author":"M Simons","year":"2002","unstructured":"Simons, M.  et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788\u2013793 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR46","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/hc1102.105595","volume":"105","author":"CL Grines","year":"2002","unstructured":"Grines, C. L.  et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291\u20131297 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/hum.2006.17.683","volume":"17","author":"YH Kusumanto","year":"2006","unstructured":"Kusumanto, Y. H.  et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 17, 683\u2013691 (2006).","journal-title":"Hum. Gene Ther."},{"key":"BFnrcardio201370_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00109-005-0031-3","volume":"84","author":"B Witzenbichler","year":"2006","unstructured":"Witzenbichler, B.  et al. Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J. Molec. Med. 84, 491\u2013502 (2006).","journal-title":"J. Molec. Med."},{"key":"BFnrcardio201370_CR49","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1067\/mva.2002.123677","volume":"35","author":"AJ Comerota","year":"2002","unstructured":"Comerota, A. J.  et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J. Vasc. Surg. 35, 930\u2013936 (2002).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR50","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/mt.2009.24","volume":"17","author":"I Baumgartner","year":"2009","unstructured":"Baumgartner, I.  et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol. Ther. 17, 914\u2013921 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrcardio201370_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/mt.2008.33","volume":"16","author":"S Nikol","year":"2008","unstructured":"Nikol, S.  et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16, 972\u2013978 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrcardio201370_CR52","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","volume":"377","author":"J Belch","year":"2011","unstructured":"Belch, J.  et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377, 1929\u20131937 (2011).","journal-title":"Lancet"},{"key":"BFnrcardio201370_CR53","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1073\/pnas.87.8.3200","volume":"87","author":"K Tashiro","year":"1990","unstructured":"Tashiro, K.  et al. Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc. Natl Acad. Sci. USA 87, 3200\u20133204 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"19 Suppl.","key":"BFnrcardio201370_CR54","first-page":"II301","volume":"100","author":"S Hayashi","year":"1999","unstructured":"Hayashi. S.  et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100 (19 Suppl.), II301\u2013II308 (1999).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","volume":"118","author":"RJ Powell","year":"2008","unstructured":"Powell, R. J.  et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118, 58\u201365 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR56","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","volume":"52","author":"RJ Powell","year":"2010","unstructured":"Powell, R. J.  et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J. Vasc. Surg. 52, 1525\u20131530 (2010).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR57","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/gt.2010.51","volume":"17","author":"H Shigematsu","year":"2010","unstructured":"Shigematsu, H.  et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 17, 1152\u20131161 (2010).","journal-title":"Gene Ther."},{"key":"BFnrcardio201370_CR58","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/CIRCULATIONAHA.110.009407","volume":"124","author":"MA Creager","year":"2011","unstructured":"Creager, M. A.  et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 124, 1765\u20131773 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc2868","volume":"10","author":"AS Chung","year":"2010","unstructured":"Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505\u2013514 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrcardio201370_CR60","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/nm1010-1107","volume":"16","author":"N Ferrara","year":"2010","unstructured":"Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16, 1107\u20131111 (2010).","journal-title":"Nat. Med."},{"key":"BFnrcardio201370_CR61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jvs.2004.11.012","volume":"41","author":"GL Tang","year":"2005","unstructured":"Tang, G. L.  et al. The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J. Vasc. Surg. 41, 312\u2013320 (2005).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1152\/japplphysiol.00107.2004","volume":"97","author":"RE Waters","year":"2004","unstructured":"Waters, R. E., Terjung, R. L., Peters, K. G. & Annex, B. H. Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents. J. Appl. Physiol. 97, 773\u2013780 (2004).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201370_CR63","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.107.736447","volume":"117","author":"AO Dokun","year":"2008","unstructured":"Dokun A. O.  et al. A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation 117, 1207\u20131215 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.niox.2009.01.002","volume":"20","author":"JD Allen","year":"2009","unstructured":"Allen, J. D.  et al. Plasma nitrite response and arterial reactivity differentiate vascular health and performance. Nitric Oxide 20, 231\u2013237 (2009).","journal-title":"Nitric Oxide"},{"key":"BFnrcardio201370_CR65","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.arr.2009.04.003","volume":"8","author":"L Sun","year":"2009","unstructured":"Sun, L., Bai, Y. & Du, G. Endothelial dysfunction\u2014an obstacle of therapeutic angiogenesis. Ageing Res. Rev. 8, 306\u2013313 (2009).","journal-title":"Ageing Res. Rev."},{"key":"BFnrcardio201370_CR66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2004.01.015","volume":"174","author":"TT Tuomisto","year":"2004","unstructured":"Tuomisto, T. T.  et al. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 174, 111\u2013120 (2004).","journal-title":"Atherosclerosis"},{"key":"BFnrcardio201370_CR67","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1172\/JCI10226","volume":"106","author":"T Nakamura","year":"2000","unstructured":"Nakamura, T.  et al. Myocardial protection from ischemia\/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511\u20131519 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio201370_CR68","doi-asserted-by":"publisher","first-page":"H1191","DOI":"10.1152\/ajpheart.2001.280.3.H1191","volume":"280","author":"Y Yamamura","year":"2001","unstructured":"Yamamura, Y.  et al. IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 280, H1191\u2013H1200 (2001).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio201370_CR69","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/01.ATV.0000202677.55012.a0","volume":"26","author":"A Helisch","year":"2006","unstructured":"Helisch, A.  et al. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler. Thromb. Vasc. Biol. 26, 520\u2013526 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio201370_CR70","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/j.1538-7836.2004.00809.x","volume":"2","author":"JL Reny","year":"2004","unstructured":"Reny, J. L.  et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case\u2013control study. J. Thromb. Haemost. 2, 1334\u20131340 (2004).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201370_CR71","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana, P.  et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case\u2013control study. Circulation 108, 2971\u20132973 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201370_CR72","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0140-6736(92)90596-U","volume":"339","author":"FG Fowkes","year":"1992","unstructured":"Fowkes, F. G.  et al. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 339, 693\u2013696 (1992).","journal-title":"Lancet"},{"key":"BFnrcardio201370_CR73","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1086\/339251","volume":"70","author":"G Gudmundsson","year":"2002","unstructured":"Gudmundsson, G.  et al. Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31. Am. J. Hum. Genet. 70, 586\u2013592 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrcardio201370_CR74","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCGENETICS.111.961292","volume":"5","author":"JM Murabito","year":"2012","unstructured":"Murabito, J. M.  et al. Association between chromosome 9p21 variants and the ankle\u2013brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ. Cardiovasc. Genet. 5, 100\u2013112 (2012).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"BFnrcardio201370_CR75","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0021-9681(79)90059-6","volume":"32","author":"A Da Silva","year":"1979","unstructured":"Da Silva, A.  et al. The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. J. Chronic Dis. 32, 797\u2013803 (1979).","journal-title":"J. Chronic Dis."},{"key":"BFnrcardio201370_CR76","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jvs.2004.08.049","volume":"40","author":"EM Willigendael","year":"2004","unstructured":"Willigendael, E. M.  et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J. Vasc. Surg. 40, 1158\u20131165 (2004).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR77","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1006\/jmcc.2002.2013","volume":"34","author":"D Scholz","year":"2002","unstructured":"Scholz, D.  et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J. Mol. Cell. Cardiol. 34, 775\u2013787 (2002).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"BFnrcardio201370_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bbrc.2003.08.134","volume":"310","author":"K Fukino","year":"2003","unstructured":"Fukino, K., Sata, M., Seko, Y., Hirata, Y. & Nagai, R. Genetic background influences therapeutic effectiveness of VEGF. Biochem. Biophys. Res. Commun. 310, 143\u2013147 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrcardio201370_CR79","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/sj.mt.6300175","volume":"15","author":"TT Rissanen","year":"2007","unstructured":"Rissanen, T. T. & Yl\u00e4-Herttuala, S. Current status of cardiovascular gene therapy. Mol. Ther. 15, 1233\u20131247 (2007).","journal-title":"Mol. Ther."},{"key":"BFnrcardio201370_CR80","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/mt.2011.3","volume":"19","author":"NM Kotchey","year":"2011","unstructured":"Kotchey, N. M.  et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19, 1079\u20131089 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrcardio201370_CR81","doi-asserted-by":"publisher","first-page":"8549","DOI":"10.1128\/JVI.73.10.8549-8558.1999","volume":"73","author":"YJ Hernandez","year":"1999","unstructured":"Hernandez, Y. J.  et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549\u20138558 (1999).","journal-title":"J. Virol."},{"key":"BFnrcardio201370_CR82","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jvs.2011.03.278","volume":"54","author":"A Saqib","year":"2011","unstructured":"Saqib, A.  et al. Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB\/c mice. J. Vasc. Surg. 54, 810\u2013818 (2011).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio201370_CR83","first-page":"A14001","volume":"124","author":"AB Katwal","year":"2011","unstructured":"Katwal, A. B.  et al. Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery in a mouse model of peripheral arterial disease [abstract A14001]. Circulation 124, A14001 (2011).","journal-title":"Circulation"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.70","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T20:31:56Z","timestamp":1650054716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnrcardio201370"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2013.70","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]},"assertion":[{"value":"14 May 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has acted as a consultant for AnGes MG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}